Neptunus Galaxy Technology Building
24th Floor No. 1 Keji Zhongsan Road Nanshan District
Shenzhen 518057
China
86 755 2698 0336
https://www.neptunusbio.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 9,093
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Feng Zhang | Vice Chairman of the Board & President | N/D | N/D | 1972 |
Mr. Da Kai Shen | Financial Director, VP & Director | N/D | N/D | 1965 |
Mr. Yi Fei Zhang | Executive VP & Director | N/D | N/D | 1973 |
Mr. Rui Jin | VP & Non-Independent Director | N/D | N/D | 1984 |
Mr. Yunlei Wang | VP & Board Secretary | N/D | N/D | 1971 |
Mr. Xiao Peng Wang | Vice President | N/D | N/D | 1970 |
Mr. Ling Luo | Vice President | N/D | N/D | 1979 |
Mr. Fan Zhang | Vice President | N/D | N/D | 1969 |
Mr. Shuangcheng Yang | Vice President | N/D | N/D | 1964 |
Mr. Xiaoming Shi | Vice President | N/D | N/D | 1976 |
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors. The company offers drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1989 and is headquartered in Shenzhen, China.
La calificación ISS Governance QuickScore de Shenzhen Neptunus Bioengineering Co., Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.